Detailed description page of ThPDB2

This page displays user query in tabular form.

Th1640 details
Primary information
ID15896
Therapeutic IDTh1640
Protein NameInterferon Kappa
Sequence>Th1640_Interferon_Kappa MSTKPDMIQKCLWLEILMGIFIAGTLSLDCNLLNVHLRRVTWQNLRHLSSMSNSFPVECLRENIAFELPQEFLQYTQPMKRDIKKAFYEMSLQAFNIFSQHTFKYWKERHLKQIQIGLDQQAEYLNQCLEEDKNENEDMKEMKENEMKPSEARVPQLSSLELRRYFHRIDNFLKEKKYSDCAWEIVRVEIRRCLYYFYKFTALFRRK
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-lifeNA
DescriptionInterferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino acid signal peptide conserved in type I interferons. This gene encoding for this interferon is expressed in human epidermal keratinocytes.
Indication/DiseaseNA
PharmacodynamicsNA
Mechanism of ActionSignificant interferon kappa expression enhancement occurs with: viral infection, exposure to double-stranded RNA, or treatment with interferon gamma or interferon beta. It was also found cellular protection against viral infection occurs in a species-specific manner. The mechanism by which IFN- acts involves the activation of the interferon-stimulated response element signalling pathway and a panel of genes which include anti-viral mediators and transcriptional regulators, similar to those regulated by other type I interferons. Also as with other type I interferons, IFN- binds at the same receptors, which are interferon-a/ß receptor 1(IFNAR1) and IFNAR2.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesAmino Acids, Peptides, and Proteins
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Brand NameNA
CompanyNA
Brand DescriptionNA
Prescribed ForNA
Chemical NameNA
FormulationNA
Physical Appearance NA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful Link 1Link
Useful Link 2NA
RemarksNA


Primary information
ID15897
Therapeutic IDTh1640
Protein NameInterferon Kappa
Sequence>Th1640_Interferon_Kappa MSTKPDMIQKCLWLEILMGIFIAGTLSLDCNLLNVHLRRVTWQNLRHLSSMSNSFPVECLRENIAFELPQEFLQYTQPMKRDIKKAFYEMSLQAFNIFSQHTFKYWKERHLKQIQIGLDQQAEYLNQCLEEDKNENEDMKEMKENEMKPSEARVPQLSSLELRRYFHRIDNFLKEKKYSDCAWEIVRVEIRRCLYYFYKFTALFRRK
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-lifeNA
DescriptionInterferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino acid signal peptide conserved in type I interferons. This gene encoding for this interferon is expressed in human epidermal keratinocytes.
Indication/DiseaseNA
PharmacodynamicsNA
Mechanism of ActionSignificant interferon kappa expression enhancement occurs with: viral infection, exposure to double-stranded RNA, or treatment with interferon gamma or interferon beta. It was also found cellular protection against viral infection occurs in a species-specific manner. The mechanism by which IFN- acts involves the activation of the interferon-stimulated response element signalling pathway and a panel of genes which include anti-viral mediators and transcriptional regulators, similar to those regulated by other type I interferons. Also as with other type I interferons, IFN- binds at the same receptors, which are interferon-a/ß receptor 1(IFNAR1) and IFNAR2.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesBiological Factors
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Brand NameNA
CompanyNA
Brand DescriptionNA
Prescribed ForNA
Chemical NameNA
FormulationNA
Physical Appearance NA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful Link 1Link
Useful Link 2NA
RemarksNA


Primary information
ID15898
Therapeutic IDTh1640
Protein NameInterferon Kappa
Sequence>Th1640_Interferon_Kappa MSTKPDMIQKCLWLEILMGIFIAGTLSLDCNLLNVHLRRVTWQNLRHLSSMSNSFPVECLRENIAFELPQEFLQYTQPMKRDIKKAFYEMSLQAFNIFSQHTFKYWKERHLKQIQIGLDQQAEYLNQCLEEDKNENEDMKEMKENEMKPSEARVPQLSSLELRRYFHRIDNFLKEKKYSDCAWEIVRVEIRRCLYYFYKFTALFRRK
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-lifeNA
DescriptionInterferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino acid signal peptide conserved in type I interferons. This gene encoding for this interferon is expressed in human epidermal keratinocytes.
Indication/DiseaseNA
PharmacodynamicsNA
Mechanism of ActionSignificant interferon kappa expression enhancement occurs with: viral infection, exposure to double-stranded RNA, or treatment with interferon gamma or interferon beta. It was also found cellular protection against viral infection occurs in a species-specific manner. The mechanism by which IFN- acts involves the activation of the interferon-stimulated response element signalling pathway and a panel of genes which include anti-viral mediators and transcriptional regulators, similar to those regulated by other type I interferons. Also as with other type I interferons, IFN- binds at the same receptors, which are interferon-a/ß receptor 1(IFNAR1) and IFNAR2.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesCytokines
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Brand NameNA
CompanyNA
Brand DescriptionNA
Prescribed ForNA
Chemical NameNA
FormulationNA
Physical Appearance NA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful Link 1Link
Useful Link 2NA
RemarksNA


Primary information
ID15899
Therapeutic IDTh1640
Protein NameInterferon Kappa
Sequence>Th1640_Interferon_Kappa MSTKPDMIQKCLWLEILMGIFIAGTLSLDCNLLNVHLRRVTWQNLRHLSSMSNSFPVECLRENIAFELPQEFLQYTQPMKRDIKKAFYEMSLQAFNIFSQHTFKYWKERHLKQIQIGLDQQAEYLNQCLEEDKNENEDMKEMKENEMKPSEARVPQLSSLELRRYFHRIDNFLKEKKYSDCAWEIVRVEIRRCLYYFYKFTALFRRK
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-lifeNA
DescriptionInterferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino acid signal peptide conserved in type I interferons. This gene encoding for this interferon is expressed in human epidermal keratinocytes.
Indication/DiseaseNA
PharmacodynamicsNA
Mechanism of ActionSignificant interferon kappa expression enhancement occurs with: viral infection, exposure to double-stranded RNA, or treatment with interferon gamma or interferon beta. It was also found cellular protection against viral infection occurs in a species-specific manner. The mechanism by which IFN- acts involves the activation of the interferon-stimulated response element signalling pathway and a panel of genes which include anti-viral mediators and transcriptional regulators, similar to those regulated by other type I interferons. Also as with other type I interferons, IFN- binds at the same receptors, which are interferon-a/ß receptor 1(IFNAR1) and IFNAR2.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesIntercellular Signaling Peptides and Proteins
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Brand NameNA
CompanyNA
Brand DescriptionNA
Prescribed ForNA
Chemical NameNA
FormulationNA
Physical Appearance NA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful Link 1Link
Useful Link 2NA
RemarksNA


Primary information
ID15900
Therapeutic IDTh1640
Protein NameInterferon Kappa
Sequence>Th1640_Interferon_Kappa MSTKPDMIQKCLWLEILMGIFIAGTLSLDCNLLNVHLRRVTWQNLRHLSSMSNSFPVECLRENIAFELPQEFLQYTQPMKRDIKKAFYEMSLQAFNIFSQHTFKYWKERHLKQIQIGLDQQAEYLNQCLEEDKNENEDMKEMKENEMKPSEARVPQLSSLELRRYFHRIDNFLKEKKYSDCAWEIVRVEIRRCLYYFYKFTALFRRK
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-lifeNA
DescriptionInterferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino acid signal peptide conserved in type I interferons. This gene encoding for this interferon is expressed in human epidermal keratinocytes.
Indication/DiseaseNA
PharmacodynamicsNA
Mechanism of ActionSignificant interferon kappa expression enhancement occurs with: viral infection, exposure to double-stranded RNA, or treatment with interferon gamma or interferon beta. It was also found cellular protection against viral infection occurs in a species-specific manner. The mechanism by which IFN- acts involves the activation of the interferon-stimulated response element signalling pathway and a panel of genes which include anti-viral mediators and transcriptional regulators, similar to those regulated by other type I interferons. Also as with other type I interferons, IFN- binds at the same receptors, which are interferon-a/ß receptor 1(IFNAR1) and IFNAR2.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesInterferons
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Brand NameNA
CompanyNA
Brand DescriptionNA
Prescribed ForNA
Chemical NameNA
FormulationNA
Physical Appearance NA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful Link 1Link
Useful Link 2NA
RemarksNA


Primary information
ID15901
Therapeutic IDTh1640
Protein NameInterferon Kappa
Sequence>Th1640_Interferon_Kappa MSTKPDMIQKCLWLEILMGIFIAGTLSLDCNLLNVHLRRVTWQNLRHLSSMSNSFPVECLRENIAFELPQEFLQYTQPMKRDIKKAFYEMSLQAFNIFSQHTFKYWKERHLKQIQIGLDQQAEYLNQCLEEDKNENEDMKEMKENEMKPSEARVPQLSSLELRRYFHRIDNFLKEKKYSDCAWEIVRVEIRRCLYYFYKFTALFRRK
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-lifeNA
DescriptionInterferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino acid signal peptide conserved in type I interferons. This gene encoding for this interferon is expressed in human epidermal keratinocytes.
Indication/DiseaseNA
PharmacodynamicsNA
Mechanism of ActionSignificant interferon kappa expression enhancement occurs with: viral infection, exposure to double-stranded RNA, or treatment with interferon gamma or interferon beta. It was also found cellular protection against viral infection occurs in a species-specific manner. The mechanism by which IFN- acts involves the activation of the interferon-stimulated response element signalling pathway and a panel of genes which include anti-viral mediators and transcriptional regulators, similar to those regulated by other type I interferons. Also as with other type I interferons, IFN- binds at the same receptors, which are interferon-a/ß receptor 1(IFNAR1) and IFNAR2.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesPeptides
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Brand NameNA
CompanyNA
Brand DescriptionNA
Prescribed ForNA
Chemical NameNA
FormulationNA
Physical Appearance NA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful Link 1Link
Useful Link 2NA
RemarksNA


Primary information
ID15902
Therapeutic IDTh1640
Protein NameInterferon Kappa
Sequence>Th1640_Interferon_Kappa MSTKPDMIQKCLWLEILMGIFIAGTLSLDCNLLNVHLRRVTWQNLRHLSSMSNSFPVECLRENIAFELPQEFLQYTQPMKRDIKKAFYEMSLQAFNIFSQHTFKYWKERHLKQIQIGLDQQAEYLNQCLEEDKNENEDMKEMKENEMKPSEARVPQLSSLELRRYFHRIDNFLKEKKYSDCAWEIVRVEIRRCLYYFYKFTALFRRK
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting pointNA
Half-lifeNA
DescriptionInterferon kappa is a subclass of type I interferon mediating host defence which consists of 207 amino acids and has 30% homology with others of the same class as it consists of a series of cysteine and a 27-amino acid signal peptide conserved in type I interferons. This gene encoding for this interferon is expressed in human epidermal keratinocytes.
Indication/DiseaseNA
PharmacodynamicsNA
Mechanism of ActionSignificant interferon kappa expression enhancement occurs with: viral infection, exposure to double-stranded RNA, or treatment with interferon gamma or interferon beta. It was also found cellular protection against viral infection occurs in a species-specific manner. The mechanism by which IFN- acts involves the activation of the interferon-stimulated response element signalling pathway and a panel of genes which include anti-viral mediators and transcriptional regulators, similar to those regulated by other type I interferons. Also as with other type I interferons, IFN- binds at the same receptors, which are interferon-a/ß receptor 1(IFNAR1) and IFNAR2.
ToxicityNA
MetabolismNA
AbsorptionNA
NA
ClearanceNA
CategoriesProteins
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Brand NameNA
CompanyNA
Brand DescriptionNA
Prescribed ForNA
Chemical NameNA
FormulationNA
Physical Appearance NA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful Link 1Link
Useful Link 2NA
RemarksNA